Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Exploring Biological Activity of 4-Oxo-4 H -furo[2,3- h ]chromene Derivatives as Potential Multi-Target-Directed Ligands Inhibiting Cholinesterases, β-Secretase, Cyclooxygenase-2, and Lipoxygenase-5/15.

Tytuł:
Exploring Biological Activity of 4-Oxo-4 H -furo[2,3- h ]chromene Derivatives as Potential Multi-Target-Directed Ligands Inhibiting Cholinesterases, β-Secretase, Cyclooxygenase-2, and Lipoxygenase-5/15.
Autorzy:
Mphahlele MJ; Department of Chemistry, College of Science, Engineering and Technology, University of South Africa, Private Bag X06, Florida 1710, South Africa.
Agbo EN; Department of Chemistry, College of Science, Engineering and Technology, University of South Africa, Private Bag X06, Florida 1710, South Africa.
Gildenhuys S; Department of Life & Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Private Bag X06, Florida 1710, South Africa.
Setshedi IB; Department of Life & Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Private Bag X06, Florida 1710, South Africa.
Źródło:
Biomolecules [Biomolecules] 2019 Nov 13; Vol. 9 (11). Date of Electronic Publication: 2019 Nov 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, 2011-
MeSH Terms:
Amyloid Precursor Protein Secretases*/antagonists & inhibitors
Amyloid Precursor Protein Secretases*/chemistry
Amyloid Precursor Protein Secretases*/metabolism
Arachidonate 5-Lipoxygenase*/chemistry
Arachidonate 5-Lipoxygenase*/metabolism
Cholinesterase Inhibitors*/chemistry
Cholinesterase Inhibitors*/pharmacology
Cholinesterases*/chemistry
Cholinesterases*/metabolism
Cyclooxygenase 2*/chemistry
Cyclooxygenase 2*/metabolism
Cyclooxygenase 2 Inhibitors*/chemistry
Lipoxygenase Inhibitors*/chemistry
Lipoxygenase Inhibitors*/pharmacology
HEK293 Cells ; Humans ; Ligands ; MCF-7 Cells ; Molecular Docking Simulation
References:
J Neurochem. 2007 Mar;100(5):1421-9. (PMID: 17212694)
Molecules. 2012 Dec 21;18(1):140-53. (PMID: 23344193)
Essays Biochem. 2014;56:99-110. (PMID: 25131589)
Neurobiol Dis. 2015 Dec;84:22-38. (PMID: 25926349)
Eur J Med Chem. 2014 Jun 10;80:47-56. (PMID: 24763362)
J Med Chem. 2005 Oct 20;48(21):6523-43. (PMID: 16220969)
Eur J Med Chem. 2018 Oct 5;158:463-477. (PMID: 30243151)
Biomed Res Int. 2014;2014:291214. (PMID: 25050335)
Nat Prod Commun. 2015 Sep;10(9):1585-7. (PMID: 26594765)
J Enzyme Inhib Med Chem. 2007 Jun;22(3):287-92. (PMID: 17674809)
Nat Rev Drug Discov. 2006 Oct;5(10):864-76. (PMID: 17016427)
Eur J Pharmacol. 2004 Feb 13;486(1):9-17. (PMID: 14751402)
J Alzheimers Dis. 2015;43(3):739-55. (PMID: 25147111)
Biochemistry. 1993 Nov 16;32(45):12074-84. (PMID: 8218285)
ChemMedChem. 2016 Oct 19;11(20):2252-2260. (PMID: 27630077)
Carcinogenesis. 2014 Aug;35(8):1788-97. (PMID: 24590894)
Molecules. 2016 Oct 02;21(10):. (PMID: 27706093)
Curr Med Chem. 2011;18(32):4949-75. (PMID: 22050745)
Eur J Biochem. 2003 Nov;270(22):4447-58. (PMID: 14622273)
Chem Soc Rev. 2011 Oct;40(10):5084-121. (PMID: 21655588)
Int J Mol Sci. 2018 Dec 18;19(12):null. (PMID: 30567381)
Eur Neurol. 2002;47(1):64-70. (PMID: 11803198)
Biochem Pharmacol. 1961 Jul;7:88-95. (PMID: 13726518)
Beilstein J Org Chem. 2008;4:13. (PMID: 18941485)
Curr Neuropharmacol. 2013 May;11(3):315-35. (PMID: 24179466)
J Pharmacol Exp Ther. 1991 Mar;256(3):929-37. (PMID: 1848634)
J Med Chem. 2014 Oct 9;57(19):8167-79. (PMID: 25226236)
Expert Opin Ther Pat. 2010 Mar;20(3):355-75. (PMID: 20180620)
Eur J Med Chem. 2018 Jan 1;143:1301-1311. (PMID: 29126732)
J Med Chem. 2013 Feb 28;56(4):1363-88. (PMID: 23145854)
Eur J Pharm Sci. 2018 Jun 5;121:356-381. (PMID: 29883727)
Beilstein J Org Chem. 2016 Sep 8;12:2005-2011. (PMID: 27829904)
Alzheimers Dement (N Y). 2016 May 30;2(2):99-109. (PMID: 29067297)
Chem Rev. 2014 May 14;114(9):4960-92. (PMID: 24555663)
J Med Chem. 2017 Oct 12;60(19):7941-7957. (PMID: 28537720)
Nat Rev Drug Discov. 2002 Sep;1(9):727-30. (PMID: 12209152)
J Med Chem. 2014 Aug 28;57(16):7073-84. (PMID: 25089370)
Neuroscience. 2013 Mar 27;234:53-68. (PMID: 23305761)
N Biotechnol. 2009 Jun;25(5):331-46. (PMID: 19491049)
Eur J Med Chem. 2019 Oct 1;179:272-309. (PMID: 31255927)
J Surg Res. 2013 Nov;185(1):300-9. (PMID: 23816246)
Eur J Med Chem. 2010 Sep;45(9):4058-64. (PMID: 20576329)
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17213-8. (PMID: 16275899)
Contributed Indexing:
Keywords: anti-oxidant activity; cholinesterases; cyclooxygenase-2; cytotoxicity; furochromones; lipoxygenases-5/15; molecular docking; β-secretase
Substance Nomenclature:
0 (Cholinesterase Inhibitors)
0 (Cyclooxygenase 2 Inhibitors)
0 (Ligands)
0 (Lipoxygenase Inhibitors)
EC 1.13.11.34 (Arachidonate 5-Lipoxygenase)
EC 1.14.99.1 (Cyclooxygenase 2)
EC 1.14.99.1 (PTGS2 protein, human)
EC 1.3.11.34 (ALOX5 protein, human)
EC 3.1.1.8 (Cholinesterases)
EC 3.4.- (Amyloid Precursor Protein Secretases)
Entry Date(s):
Date Created: 20191127 Date Completed: 20200818 Latest Revision: 20200818
Update Code:
20240104
PubMed Central ID:
PMC6920776
DOI:
10.3390/biom9110736
PMID:
31766252
Czasopismo naukowe
A series of 5-oxo-5 H -furo[3,2- g ]chromene-6-carbaldehydes and their hydrazone derivatives were evaluated as potential multi-target-directed ligands in vitro against cholinesterases, β-secretase, cyclooxygenase-2, and lipoxygenase-15 (LOX-15), as well as for free radical-scavenging activities. The most active compounds against LOX-15 were also evaluated for activity against the human lipoxygenase-5 (LOX-5). Kinetic studies against AChE, BChE, and β-secretase (BACE-1) were performed on 2-(3-fluorophenyl)- ( 3b ) and 2-(4-chlorophenyl)-6-[(4-trifluoromethylphenyl)hydrazonomethyl]furo[3,2- h ]chromen-5-one ( 3e ) complemented with molecular docking (in silico) to determine plausible protein-ligand interactions on a molecular level. The docking studies revealed hydrogen and/or halogen bonding interactions between the strong electron-withdrawing fluorine atoms of the trifluoromethyl group with several residues of the enzyme targets, which are probably responsible for the observed increased biological activity of these hydrazone derivatives. The two compounds were found to moderately inhibit COX-2 and lipoxygenases (LOX-5 and LOX-15). Compounds 3b and 3e were also evaluated for cytotoxicity against the breast cancer MCF-7 cell line and Hek293-T cells.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies